Oxford and Newcastle, UK – 10 March 2015 – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its full year results for the period ended 31 January 2015 on Tuesday, 31 March 2015.
A group analyst briefing will be held at 11:30am on Tuesday, 31 March 2015 at Instinctif Partners’ offices at 65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email e-therapeutics@instinctif.com to register.
- ENDS -
Issued for and on behalf of e-Therapeutics by Instinctif Partners.
For more information please contact:
e-Therapeutics plc
Steve Medlicott
Tel: +44 (0) 1993 883125
www.etherapeutics.co.uk
N+1 Singer
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000
www.n1singer.com
Instinctif Partners
Melanie Toyne-Sewell / Emma Barlow
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@instinctif.com
Notes To Editors
About e-Therapeutics plc
e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is currently focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk
Help employers find you! Check out all the jobs and post your resume.
